Neurotoxicity-related to CAR-T therapy: Proposed protocol and preliminary data from Bologna

Chimeric antigen receptor (CAR) T-cells therapy is an effective treatment for haematological malignancies, yet hampered by cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)1, a neuropsychiatric syndrome whose biological underpinnings are still unravelled2,3. We present our neurological protocol to manage ICANS and preliminary data.